Prostate Cancer Trial, Recruiting NCT02016248 Sponsor: MemorialCare Health System Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT02016248
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with prostate cancer confirmed through a tissue sample (biopsy).
  • You have had a biopsy within the last 12 months before signing up, unless your cancer already qualifies you for the higher-risk group in this study (confirm with trial site for details on whether a new biopsy is needed).
  • Your cancer is at a stage from I (early) to IV (more advanced) but has not been confirmed to have spread to distant parts of the body (Stage MX-M0).
  • Your cancer stage has been assessed using methods such as a physical exam, CT scan, MRI, bone scan, PSMA PET/CT scan, or biopsy.
  • Your prostate is recommended to be no larger than 100 cc in volume, measured by CT, MRI, or ultrasound taken within the last 90 days (this is recommended but not strictly required).
  • You are generally active and able to carry out daily activities with little or no limitation (known as ECOG performance status 0-1; confirm with trial site).
  • You have completed the required patient questionnaires for the study.
  • You have signed a consent form to participate.

Who may not be able to join:

  • You have previously had surgery to remove your prostate or had cryotherapy (freezing treatment) on your prostate.
  • You have previously had radiation therapy to your prostate or the lower pelvic area.
  • You have implanted devices or materials in your body (such as metal hardware) that could interfere with treatment planning or delivery, in the opinion of the study doctor.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Asif Harsolia, MD, MemorialCare

Phone: 562-933-9068

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
MemorialCare Health System
Registry
ClinicalTrials.gov
Start date
1 June 2012
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rate of Grade 3-5 Gastrointestinal (GI) and Genitourinary (GU) Toxicities

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov